Infliximab is a monoclonal antibody against TNF-α which was used to neutralize activity by binding to soluble and transmembrane forms of TNF-α and stopping interactions with its receptors in a syngeneic model of breast cancer in BALB/c mice to understand its primary effect on tumor progression. Here, TNF is linked to breast carcinoma.